Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Expands By 34.9%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 39,000 shares, an increase of 34.9% from the November 15th total of 28,900 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is presently 0.0 days. Approximately 1.7% of the shares of the company are short sold.

ZyVersa Therapeutics Price Performance

Shares of NASDAQ:ZVSA opened at $1.05 on Friday. The company’s fifty day moving average is $1.61 and its two-hundred day moving average is $2.83. ZyVersa Therapeutics has a 1-year low of $0.98 and a 1-year high of $25.00.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.